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Introduction: This review provides a synopsis for clinicians on the use of antiepileptic drugs (AEDs) in the
breastfeeding mother.
Methods: For each AED, we collected all retrievable data from Hale’s “Medications and Mother Milk” (2012), from
the LactMed database (2013) of the National Library of Medicine, and from a MedLine Search of relevant studies in
the past 10 years.
Results: Older AEDs, such as carbamazepine, valproic acid, phenytoin, phenobarbital, primidone are considered to
have a good level of safety during lactation, due to the long term clinical experience and the consequent amount
of available data from the scientific literature. On the contrary, fewer data are available on the use of new AEDs.
Therefore, gabapentin, lamotrigine, oxcarbazepine, vigabatrin, tiagabine, pregabalin, leviracetam and topiramate are
compatible with breastfeeding with a less documented safety profile. Ethosuximide, zonisamide and the continue
use of clonazepam and diazepam are contraindicated during breastfeeding.
Conclusions: Although the current available advice on the use of AEDs during breastfeeding, given by different
accredited sources, present some contradictions, most AEDs can be considered safe according to our review.
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Breastfeeding is known for its beneficial effects on both
mothers and infants [1,2]. Nevertheless, in mothers suf-
fering from epilepsy or bipolar disorders treated with
antiepileptic drugs (AEDs), some concerns on infant
health may raise. The decision to encourage breast-
feeding in those women should be taken after a careful
evaluation of the possible side-effects on the infant
caused by the indirect exposure to AEDs via breast milk.
Data on the use of AEDs by the nursing woman are
mainly represented by single pharmacologic or pharma-
cokinetic studies and/or by case reports or case series on
the side-effects attributed to their presence in breast
milk. Moreover, toxicological and clinical data on AEDs
during breastfeeding are dispersed in the scientific litera-
ture and consequently not easily accessible to health
professionals called to give an evidence-based clinical
advice. The present paper aims at providing the clinician
with an updated synopsis of the lactation risk of AEDs.* Correspondence: lorenza.matarazzo@gmail.com
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Drugs considered for the present review have been se-
lected as the most frequently used among those catego-
rized as major antiepileptic (Code N03) by the Anatomical
Therapeutic Chemical Classification System (ATC) [3]
together with the anxiolytic diazepam (N05BA01). Before
assessing the lactation risk of each AED, we have collected
information on their main pharmacokinetic parameters:
plasma protein binding, half-life, milk-to-plasma ratio,
oral bioavailability (see Table 1 for definitions). We de-
cided to present data on AEDS pharmacokinetic parame-
ters as they represent the theoretical basis on which the
lactation risk assessment should be developed. As an ex-
ample, we can assume that if a drug has a short half-life
(<3 hours), its level in the maternal plasma will be declin-
ing when the infant feeds again, considering a 3-hour
interval. Moreover, if the drug is highly protein bound, it
cannot enter the milk compartment easily. Milk/plasma
ratio has the primary use of quantifying the extent of drug
transfer into the milk; nevertheless, its use in assessing a
lactation risk is limited as the amount of drug transfer into
milk is mainly determined by the maternal plasma level.
Medications for the breastfeeding mother should have a
low oral bioavailability, as the result of either a poor gutal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Definitions and clinical relevance of the pharmacokinetic parameters used to assess the lactation risk
following maternal intake of medications
Pharmacokinetic parameter Definition
Half-life or “T ½” The half-life of a substance is the time it takes for its plasma concentration to halve. If the half-life is long (>12-24 hrs),
drugs may accumulate in maternal plasma and the time of drug transfer from plasma to breast milk is longer.
Maternal plasma protein
binding (PB)
This parameter is expressed in percentage. The higher the percentage of the drug bound to the maternal plasma
proteins, the less the drug passes into breast milk. An ideal drug to be taken during breastfeeding should have a
plasma protein binding > 80%.
Milk-to-plasma ratio (M/P) It denotes the ratio of the drug concentration in the mother’s milk (M) divided by its concentration in the mother’s
plasma (P). It is an indicator of drug transfer into breast milk. A M/P ratio greater than 1.0 suggests that the drug may
be present in breast milk in high concentrations.
Oral bioavailability It describes the fraction of one orally administered dose of a drug that reaches the systemic circulation. It is expressed
as a percentage of the administered dose. When the intestinal absorption of a drug is impaired, the risk of adverse
effects may be lower.
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plasma compartment. Table 2 summarises each AED main
pharmacokinetic characteristics.
Beyond presenting pharmacokinetic parameters on
AEDs, we chose to collect more relevant clinical param-
eters such as the theoretical infant dose (TID), the thera-
peutic dose in the neonatal period and the relative infant
dose (RID). All these parameters were reported in a table





Clonazepam 50 – 86 100
Diazepam 99 100
Ethosuximide NA 100
Gabapentin < 3 50 – 60
Lamotrigine 55 98
Levetiracetam < 10 100
Oxcarbazepine 40 100
Phenobarbital 51 80 – 100








† PB: maternal plasma protein binding expressed as percentage.
‡ Oral Bioavailability: intestinal absorption after oral administration expressed as pe
§ T ½: half-life of the drug.
¶ M/P: milk to plasma ratio of a drug concentration.
Data drawn from references 1–8 except where otherwise specified. NA: indicates thrisk (see below), in order to have a clinical overview of
each AED.
TID is the maximum estimated amount of ingested drug
with breast milk; in other words, it is the estimation in
milligrams per kilogram per day of the theoretical infant
dose (TID). We calculated it by using the formula by
Atkinson (TID = daily breast milk intake (150 ml/kg/day) ×
maximum breast milk concentration of medication). [4]
As AEDs may be used in the neonatal period as therapy,drugs
T ½ § M/P¶
(hours)
18 – 54 0.69
18 – 50 0.33
43 0.2 – 2.7
30 – 60 0.94
5 – 7 0.7 – 1.3
29 0.057 – 1.47 [33]
6 – 8 0.76 – 1.55 [37,38]
9 (oxcarbazepine metabolyte) 0.5
20 – 133 0.4 – 0.6
(45–500 in newborns) [41]
6 – 24 0.18 – 0.45
(20–160 in preterm infants) [48]
6 NA
5 – 18 0.72
7 – 9 NA




rcentage of the administered dose.
at no data are available.
Table 3 Clinical relevant parameters for each antiepileptic drug and assessment of their lactation risk
Drug TID† Neonatal therapeutic
oral dose
RID‡ Assessment of the lactation risk according to:
(mg/kg/day) (%) Hale
2012§
LactMed 2013 Present study
(mg/kg/day) (including adverse drug reactions)
Carbamazepine 0.7 10 - 20 3.8 - 5.9 L2 ▪ CBZ levels are relatively high in breast milk Safe
▪ Breastfed infants have serum levels that are usually
below the therapeutic range.
▪ Side effects were rarely reported as sedation,
decreased suckling, withdrawal reactions and 3 cases
of liver dysfunction.
▪ Infant should be monitored for jaundice,
drowsiness, adequate weight gain, and
developmental milestones especially in premature
infants, exclusively breastfed and in combination
with other antipsychotics.
Clonazepam 0.002 0.1 - 0.2 2.8 L3 ▪ Monitor growth, sedation, developmental
milestones, especially in preterm neonates,
exclusively breastfed infants and if mother is
receiving psychotropic drugs.
Contraindicated
▪ Monitoring of serum concentration in breastfed
infant, if excessive sedation occurs.
Diazepam 0.05 IV dose available: 7.1 L3 ▪ Accumulates in maternal milk and serum of
breastfed infant. Other agents are preferred,





▪ Single dose does not require delaying feeding.0.5 – 1 [76]
Ethosuximide 11.5 15 – 40 31.4-73.5 L4 ▪ Monitor infant for drowsiness, adequate weight
gain and psychomotor development.
Contraindicated
▪ Measurement of an infant serum level might help
rule out toxicity, if there is a concern.
Gabapentin 1.7 Only paediatric
dose available:
1.3 - 6.6 L2 ▪ Monitor the infant for drowsiness, adequate weight
gain, and developmental milestones, especially in
younger, exclusively breastfed infants and when




Lamotrigine 0.7 1-6 with valproate, 5-15
with enzyme
inducing AEDs
9.2 L3 ▪ It is not necessary to discontinue
breastfeeding, but any adverse effects such as
apnoea, rash, drowsiness, decreased sucking are
to be monitored and serum levels are to be
measured.
Moderately safe
▪ Monitoring of the platelet count may also be
advisable.
Levetiracetam 3.9 5 - 10 [78] 3.4 - 7.8 L3 ▪ Monitor infant for the appearance of sleepiness,
increase appropriate weight, normal psychomotor
development.
Moderately safe
Oxcarbazepine NA 27.7 – 50 1.5-1.7 L3 ▪ Monitor the infant for drowsiness and decreased
feeding, and developmental milestones especially
in the first 2 months of life.
Moderately safe
(<18 years) [72]
Phenobarbital 0.4 3-4 24 L3 ▪ The presence of phenobarbital in breast milk may
mitigate possible neonatal abstinence.
Safe
▪ Monitor the breastfed infant for the possible
onset of drowsiness, adequate weight gain and
developmental milestones, especially in younger,
exclusively breastfed infants and antiepileptic
polytherapy.
▪ Measurement of the infant’s serum drug
concentration might help rule out toxicity.
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Table 3 Clinical relevant parameters for each antiepileptic drug and assessment of their lactation risk (Continued)
Phenytoin 0.4 5-8 0.6-7.7 L2 ▪ The proportion ingested by infants is small and
generally brings about no problems except in rare
cases of idiosyncratic reactions.
Safe
Pregabalin NA 5-14 [79] NA L3 ▪ Compatible with breastfeeding. Moderately Safe
▪ An alternate drug may be preferred, especially
while nursing a newborn or preterm infant.
Primidone 0.9 12-20 8.4-8.6 L3 ▪ The presence of phenobarbital in breast milk may
mitigate possible neonatal abstinence.
▪ Monitor the breastfed infant for the possible
onset of drowsiness, adequate weight gain and
developmental milestones, especially in younger,
exclusively breastfed infants and antiepileptic
polytherapy.
Safe
▪ Measurement of the infant’s serum drug
concentration might help rule out toxicity.
Tiagabine NA <12 years: limited data
available.
NA L3 ▪ Monitor the infant for the onset of drowsiness,
for adequate weight gain and for developmental
milestones especially in younger, exclusively
breastfed infants and when using combinations
of anticonvulsant or psychotropic drugs.
Moderately safe
▪ Other drugs should be preferred especially while
nursing a newborn or preterm infant.
Topiramate 0.3 1 - 6 24.5 L3 ▪ Monitor the infant for the onset of diarrhea,




Valproate 0.7 Limited data available
in the neonatal period.
1.4-1.7 L3 ▪ Breastfed infants are at risk for hepatotoxicity. Safe
▪ Monitor the infant for unusual bleeding
(a case of thrombocytopenia has been reported).
Vigabatrin 0.1 25-50 1.5 – 2.7 L3 ▪ Until more data are available, vigabatrin should




Zonisamide 1.9 5 – 8 28.9 -36.8 L4 ▪ Monitor infant for drowsiness, adequate weight
gain and psychomotor development.
Contraindicated
▪ Measurement of an infant serum level might help
rule out toxicity if there is a concern.
† TID theoretical infant dose.
‡ RID relative infant dose.
§ Hale lactaction risk categories: L1: safe drugs at the highest level, L2: safe, L3: moderately safe; L4: possibly dangerous, L5: contraindicated. Present study risk categories: The
moderately safe category has a less documented safety profile due to a short clinical experience and lack of studies. The moderately safe AEDs can be used, but the lowest
dose of the drug should be chosen and the nursing infant should be clinically monitored and, when possible, his/her plasma level should be checked.
Data drawn from reference 1,41 except where otherwise specified. NA: indicates that no data are available.
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day in order to have a direct comparison with the TID. A
therapeutic dose which is higher than the TID reassures of
the drug safety during breastfeeding. RID represents one
of the most useful parameters for assessing the lactation
risk. RID is calculated by dividing the infant dose via milk
in “mg/kg/day” by maternal dose in “mg/kg/day”, assum-
ing a 70 kg weight. [5] Many authors agree that anything
less than 10% of the maternal dose is considered probably
safe [5].
To review the lactation risk of AEDs, we consulted the
following two most accredited English sources: Medica-
tions and Mother’s Milk 2012, a Manual of Lactational
Pharmacology [1], and the 2013 Lactmed database (inTOXNET) [6] of the National Library of Medicine. In
his textbook, updated every two years, Hale collects data
on many current medications and their use during
breastfeeding. After evaluating information on pharma-
cokinetics and what is currently published in the scien-
tific literature for each drug, including its reported side
effects, he makes a personal recommendation, using a 5
categories of lactation risk: L1: safe drugs at the highest
level, L2: safe drugs, L3: moderately safe drugs, L4: drugs
possibly dangerous, L5: contraindicated drugs. LactMed
database is part of the National Library of Medicine’s
Toxicology Data Network (TOXNET), and it includes
information on the levels of drugs and other chemicals
to which breastfeeding mothers may be exposed in
Davanzo et al. Italian Journal of Pediatrics 2013, 39:50 Page 5 of 11
http://www.ijponline.net/content/39/1/50breast milk and infant blood, together with the possible
adverse effects in the nursing infant. All data published
in LactMed are derived from the scientific literature and
fully referenced.
To complete our synopsis, we have also performed a
non-systematic Medline search of the literature with the
keywords “antiepileptic drugs” AND “breastfeeding”, re-
trieving studies from 2004 to April 9th 2013 , including
the most relevant and up-dated studies on lactation risk.
Data from the Committee on Drugs of the American
Academy of Pediatrics (AAP) [7], and the Goodman &
Gilman’s Textbook of Pharmacology [8] were also included
in our review.
For each AED we organized the relevant data into
small summaries.
As the result of our review we classified AEDs in 3
categories: safe, moderately safe and contraindicated
during breastfeeding. The moderately safe category has a
less documented safety profile due to a short clinical
experience and lack of studies. However, the moderately
safe AEDs can be used with caution. The lowest dose of
the drug should be chosen and the nursing infant should




Benzodiazepines (BDZ) are multiple-action psychoactive
compounds. Therefore, they may be used as anxiolytics,
antiepileptics, sedatives, hypnotics, muscle relaxants,
and as coadjuvants in anaesthesia induction. Simplifying,
we can state that all BDZ produce all these effects, albeit
with different expression of their principal effect (relative
selectivity).
In general, the first step to judge the safety of BDZ
during lactation is to know their half-life (short, inter-
mediate, long). Independently of other kinetic character-
istics, the longer is a drug half-life, the longer is its
passage into maternal milk, and the greater is the infant
metabolic effort to metabolize the drug. Both diazepam
and clonazepam have long half-life (diazepam 43 hours,
clonazepam 18–50 hours) [1]. Consequently, their pri-
mary risk to the infant is drug accumulation, which also
depends on the infant metabolism (i.e. slower in preterms)
and the therapy duration. Intermittent, short-term therapy
(24–72 h), carries a negligible risk of accumulation,
whereas prolonged use of a long half-life BDZ such as
diazepam and clonazepam, carries a greater risk. In the
meanwhile, there is no lactation risk after a single dose of
BZD, as no drug accumulation occurs.
Diazepam is highly protein bound and its transfer into
breast milk is variable. Concentrations of diazepam and
its metabolite desmethyldiazepam in maternal milk vary
between 7.7 and 87 ng/L and 19.2 and 77 ng/L, respectively[9]. Its active metabolite tends to accumulate during
prolonged lactation. Lethargy and difficult feeding have
been attributed to diazepam during breastfeeding [10].
Maternal plasma peak usually occurs within 2 h. By
delaying feeding, the infant exposure to diazepam with
maternal milk can be reduced.
Despite its scarce transfer into maternal milk, clonaze-
pam was reported to cause irregular breathing, apnea and
cyanosis in the first 10 days of life in an infant whose
mother had been taking the drug also during pregnancy.
The child psychomotor development at 5 months was
normal [11]. On the contrary, in the study of Birnbaum,
no side effects on breastfed infants were reported by
mothers treated with benzodiazepines in association with
antidepressants [12]. Clonazepam has a later plasma peak
(2–6 hours) which limits the feasibility of delaying feeding
in order to reduce the infant exposure.
Carbamazepine
Carbamazepine (CBZ) is a broad-spectrum anticonvul-
sant, also used in psychiatric disorders (such as schizo-
phrenia) and in trigeminal neuralgia. If taken during
pregnancy, its concentration compared to the maternal
serum level ranges 60-76% in the umbilical cord and 32-
80% in breast milk [13]. Most available studies on carba-
mazepine in human milk usually refer to women under
anticonvulsant polytherapy with possible interference
between drugs.
The CBZ and its active epoxide metabolite (ECBZ) are
poorly excreted into breast milk (M/P: 0.69 and 0.79 re-
spectively), partly due to the good plasma protein bind-
ing. CBZ concentration in breast milk in the current
literature is widely variable (0.34-6 mg/L) [14–17]. Its
RID is low (3.8-5.9%) [1] and serum levels in babies are
usually low, while ECBZ is not detected at all [18–20].
LactMed Database suggests to monitor breastfed in-
fants for adequate growth and possible onset of sedation
and jaundice, given some case reports of liver dysfunc-
tion with cholestasis (increase in transaminases and
gammaGT) [21,22]. Nevertheless, the drug is considered
compatible with breastfeeding [7,22–25]. In fact, it is ad-
ministered, with a good safety profile, directly to patients
of pediatric age.
Ethosuximide
Ethosuximide is used in the treatment of absence sei-
zures. Protein binding of the drug is insignificant. Its
half-life is shorter in children (30–60 h) than in adults
(about 45 h) and the M/P ratio is 0.94 [1]. The amount
of ethosuximide excreted in breast milk leads to a rele-
vant RID (31.4-73.5%) [1], which explains the significant
serum concentrations in breastfed infants (15–40 mg/L)
[26]. Although the study of Rane reported some neuro-
logical symptoms in breastfed infants (hyperexcitability,
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antiepileptic polytherapy of their mothers and/or to the
combination with withdrawal symptoms [27]. Ethosu-
ximide is considered to be potentially dangerous during
lactation [1] and monitoring breastfed infant has been
suggested [26].Gabapentin
Gabapentin is used in the treatment of partial epilepsy,
cluster headache [28], neuralgia, post-caesarean delivery
pain [2] and some psychosis. Gabapentin has a medium
half-life and is believed to accumulate in the fetus, while
it does not concentrate in breast milk (average M/P =
0.7-1.3) [1,29], leading to low serum levels and no side
effects in breastfed infants [29,30].
Lamotrigine
In fetuses exposed to lamotrigine, concentrations are
highest at birth and then gradually decline over time,
more quickly if the infant is not breastfed [31]. Some of
the pharmacokinetic characteristics of lamotrigine, such
as the long half life (29 hours) and the low protein bind-
ing (55%) [1] together with a recent reported case of
severe toxicity [32], warrant attention towards its use
during breastfeeding. The anecdotal case by Nordmo
refers to a 16 days-old-infant whose mother had shown
visual disturbances and dizziness, after taking a high
dose of lamotrigine (850 mg/day) [32]. Soon after, the
baby had a series of episodes of apnea followed by a
cyanotic crisis which requested resuscitation. Plasma
level of lamotrigine in that infant was consistently high
(4.87 μg/mL). After discontinuing the drug, the infant
recovered.
The excretion of lamotrigine in breast milk is largely
variable. A study on 30 breastfeeding women, treated for
more than 7 days with lamotrigine at doses 300–
450 mg/day, showed that breast milk samples collected
over 24 h contained 0.5-18.1 μg/mL of lamotrigine [33].
The M/P ratio ranged from 0.057 to 1.47. [1,33] The
dose that the breastfed infant would take has been calcu-
lated between 0.37 and 0.65 mg/kg/day, well below the
dose given to infants affected by epilepsy resistant to
common antiepileptic drugs [34,35]. The average RID is
9.2 (33).
Liporace reports that serum concentrations of lamotrigine
in breastfed children in some cases reach therapeutic ranges
[36]. These high levels may be explained by the genetic
variability in the neonatal glycuroconjugation responsible for
lamotriginemetabolism [36].
When maternal plasma levels are 4.5-13.4 μg/mL,
breastfed infant plasma levels are 0.6-1.8 μg/mL, with a
M/P ratio 0.413% on average [33]. Moreover laboratory
tests (electrolytes, hepatic function tests, complete bloodcount) have been all normal, except from a modest
thrombocytosis (range: 329.000–652.000/mm3 PLT, in 7
out of 8 infants tested) [33]. Eventually, Newport et al.
reassure on lamotrigine use while breastfeeding, as no
adverse effects was reported in the nursing infants in
their study [33].
In conclusion, lamotrigine is considered moderately
safe during breastfeeding [1,30], and LactMed recom-
mends to check its plasma level and to carry out a platelet
count in infants whose mothers are on lamotrigine [6].
Levetiracetam
Levetiracetam is a new AED, and is usually added to
other drugs in case of inadequate control of seizures. It
significantly passes into breast milk (M/P: 0.76-1.55)
[5,37,38], it is completely absorbed orally and it has a
pediatric half-life of about 18 hours with a low RID (3.4-
7.8%) [1].
Serum levels of levetiracetam in breastfed infants are
low (<21 μmol/L) and no side-effects have been reported
when doses between 1.3 and 3 g/day are administered to
their mothers [37,38].
Consequently, levetiracetam is usually considered com-
patible with breastfeeding [1,37,38], even if associated to
other AEDs such as primidone and phenobarbital [39].
Oxcarbazepine
Oxcarbazepine (OXC) is a pro-drug which is converted
in its active metabolite (10-OH-carbazepine) (10-OH-CBZ)
in the liver. Reports of its use while breastfeeding are lim-
ited. Most information is obtained by the paper of Lutz:
oxcarbazepine has a long half-life (9 h), a low M/P ratio
(0.5) and a low concentration in human milk (<11 μg/mL)
with a low RID (1.5-1.7%) [40]. It lacks side effects in
breastfed infants. Blood levels in infants of OCX and 10-
OH-CBZ are negligible (both <0.2 μg/mL). Therefore, we
can consider OXC moderately safe in the breastfeeding
mother.
Phenobarbital
Phenobarbital is widely used in both adults and children.
Its metabolism is mainly hepatic. The extremely long
half-life in the pediatric age (20–133 hours in infants
and up to 500 hours in newborns) [41] and the lower
plasma protein binding in neonates compared to adults
(3-43% vs 51%) could explain why its blood levels may
be higher in newborns than in their mothers.
The main, yet rare, side-effect attributed to phenobar-
bital is sedation, holding true in adults as well as in
breastfed babies. This occurrence is reported more fre-
quently in infants whose mothers are in polytherapy,
because they are likely to be exposed to interactions be-
tween drugs with possible enhancement of both clinical
and side effects [39].
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dosage 5–7 mg/kg/day in newborns affected by seizures
or drug-abstinence syndrome. This dose is far higher
than the estimated dosage (2–4 mg/day) received by a
breastfed infant by a woman taking 150 mg (a high dose)
phenobarbital per day. Given these data, there is no need
to discontinue breastfeeding in mothers treated with
phenobarbital. However, AAP is more cautious and
recommends to monitor all breastfed infants whose
mothers are on phenobarbital [7]. In premature babies
or in infants with drowsiness, difficulty in sucking or
poor weight gain, it is recommended to monitor its
plasma levels [6,42–44].Phenytoin
Despite the formerly reported methemoglobinemia in in-
fants [45], phenytoin is considered to be safe in lactation
[5,46,47], as it is highly bound to plasma proteins (89%)
[1], it scarcely passes into breast milk (M/P: 0.18-0.45)
[1,48,49] and has low concentration in human milk [49].
In fact, milk concentration of phenytoin has been
reported to be only 1.9 mg/L following maternal intakes
equal to 300–600 mg [50]. The amount ingested by
nursing infants is usually low (RID 0.6-7.7%) [1].Pregabalin
Pregabalin is used to treat postoperative [51] and neuro-
pathic pain and some psychosis. There are no studies on
the passage of pregabalin into human milk. The absence
of binding to plasma proteins and its excellent oral bio-
availability [52] suggest that it can pass into the mother’s
milk and into the circulation of the nursing infants.
Numerous side effects such as dizziness, drowsiness,
impaired vision have been observed in adults. It is rated
as moderately safe during breastfeeding [1].Primidone
Primidone is metabolized to phenobarbital and other
derivates. Serum levels of primidone and its metabolites
in breastfed infants could be close to the therapeutic
range values and cases of sedation and poor feeding are
reported in literature. It should be used with caution
during breastfeeding [14,42,43,53,54], also according to
the AAP [7]. The clinical assessment of its use during
breastfeeding is similar to phenobarbital.Tiagabine
Tiagabine oral absorption is almost complete and it is
highly bound to plasma proteins [41]. There are no stud-
ies on its use during breastfeeding, leading to possibly
prefer other antiepileptic drugs. If taken by the nursing
mother, infant should be monitored [46].Topiramate
Topiramate use is increasingly prescribed, being effective
and well-tolerated by epileptic patients. It is rapidly
absorbed, it has a low plasma protein binding, a rela-
tively long half-life and a significant excretion into breast
milk (M/P:0.86-1.1) [1,55] with a high RID (24.5%) [1].
Despite these characteristics may raise some concerns
on its use during breastfeeding, breastfed infants have
been found to have very low serum levels (<2.8 μmol/L)
in the first 3 months of life after maternal intakes of
150–200 mg/day of topiramate in association with CBZ
[55]. These low serum levels seem to depend on the in-
fant good capability to eliminate topiramate, possibly
facilitated by CBZ enzyme induction [55]. Moreover,
infants who were breastfed by mothers treated with
topiramate did not show side-effects. Notwithstanding,
they should be monitored [55,56].
Valproate
Patients taking valproate may develop hepatotoxicity,
thrombocytopenia and anemia. The limited passage of
valproate into breast milk (the drug is almost completely
bound to plasma proteins) make it safe in lactation.
[23,24,46,47] Serum levels in breastfed infants are low
[18]. However, some controversies exist on its safety
profile. The teratogenic effect of valproate exposure in
pregnancy [57], together with the decrease of methyla-
tion in the DNA extracted from the umbilical cord blood
[58] and a report of a breastfed infant with thrombocyto-
penia, purpura and anemia [59], induce a cautious use of
this AED during breastfeeding [1]. Although there is no
indication to perform routine laboratory investigations, in
case of late jaundice, it is reasonable to assess the
hepatobiliary function and to test its plasma levels in the
breastfed infant [23,46,57–62].
Vigabatrin
Vigabatrin is commonly used for multi-resistant epi-
lepsy. The maternal plasma concentration is 93 μmol/L
following an intake of 1.5 g vigabatrin. There are no pre-
cise data about its passage into breast milk. Since no
information is available about its use during lactation,
the nursing infants should be monitored [46].
Zonisamide
Zonisamide is a broad-spectrum anticonvulsant with a
half-life of nearly 63 hours [1], even if some authors re-
port a longer one (109 hours) [63]. It easily passes into
breast milk (M/P: 0.93) [6,64]. Although no studies
document side-effects in children of mothers receiving
zonisamide, due to a very high RID (28.9-36.8%), it has
been considered contraindicated by some authors [1].
Others authors simply recommend measurement of
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cern [6].
Table 2 summarises each AED main pharmacokinetic
characteristics. Table 3 gives an overview of the clinical
relevant parameters for each antiepileptic drug (TID,
therapeutic dose, RID) and the assessment of their lacta-
tion risk according to the two main sources (Hale and
LactMed) and to our study group.
Discussion
The use of AEDs is often unavoidable for most mothers
with epilepsy. Moreover, the post partum period is a vul-
nerable time for women with epilepsy, owing to the
changes in the drug metabolism and possibly to sleep
deprivation. Both these conditions may trigger an epilep-
tic crisis [65].
As the newborn might be indirectly exposed to AEDs
via breast milk, pharmacologically treated epilepsy has
been and sometimes is still considered a contraindica-
tion to breastfeeding, irrespective of which AED is taken
by the mother [66]. On the contrary, health professionals
have currently become more aware of the need to weigh
the short and long-term risks for the nursing infant
against the well demonstrated nutritional, immuno-
logical, developmental, economic and ecological benefits
of breastfeeding [1,2,67]. When evaluating the safety
profile of an AED during lactation, the physician should
collect and process data which are often dispersed in the
scientific literature and difficult to retrieve [66]. We have
therefore completed the present review in order to facili-
tate the consultancy on the use of AEDs during breast-
feeding.
The comparison of advices from the main and most
recent accredited literature sources has highlighted the
existence of a certain degree of inconsistency [66], which
is probably the consequence of the combination of lim-
ited scientific evidence and of a certain degree of arbi-
trariness. This heterogeneity of advice is not specific of
AEDs. We have previously documented a metavariability
in the assessment of the lactation risk of other classes of
drugs, such as beta-blockers [68], corticosteroids [69]
and antidepressants [70].
Evaluating the lactation risk of any drug is complex
and should take into account several aspects. In our re-
view, we have shown that neither pharmacokinetic infor-
mation nor more clinical parameters (such as TID and
RID) are alone good predictors of the lactation risk. As
an example, a drug such as phenobarbital, which is
poorly bound to the mother plasma proteins and has a
relatively long half-life and an high RID, can still be con-
sidered compatible during breastfeeding [1].
When evaluating the lactation risk of a drug, we
should always check whether or not toxicity in breastfed
infants is reported. AEDs are expected to determine inthe nursing infant a series of symptoms related to their
pharmacological effects on the central nervous system,
such as altered sleep patterns, abnormal tone, poor feed-
ing and possibly poor growth secondary to inadequate
breast sucking. However, the clinical relevance of these
attributed side-effects vary widely. As an example, the
lactation risk of infant apnea after maternal use of clo-
nazepam [11] deserves a higher level of caution than the
risk of infant sedation after maternal use of CBZ.
Another variable to take into account when consider-
ing the infant tolerance to AEDs, is his/her ability to
metabolize the drug. This is much lower when the ma-
ternal treatment begins before or during pregnancy (as
the exposure of the baby through breast milk adds to
the one through the placenta), or in case of prematurity
and during the first 2 months of life [71]. Maternal
polytherapy is also expected to increase the lactation
risk, as the result of the possible synergistic interaction
of different medications [39].
We might also speculate that the alleged long-term nega-
tive effects on child psychomotor development resulting
from the passage of small amounts of the drug through
breast milk, though up to now not well-documented,
could be well-balanced by the benefits that breast-
feeding confers to the cognitive, social and relational
development. This hypothesis seems to be supported by
the results from a study conducted in the US on 199
children exposed in uterus to AEDs (phenytoin, carba-
mazepine, valproate and lamotrigine) and followed in
the first 3 years of life. In this cohort, there was no sig-
nificant difference regarding cognitive scores between
breastfed and not breastfed children [24].
Breastfeeding mothers should be provided sound and
clear information on the lactation risk of the prescribed
medications. Nevertheless, breastfeeding mothers taking
AEDs happen to receive inconsistent and sometimes
conflicting advices on whether or not to breastfeed from
different clinicians (general physician, neurologist, pedia-
trician, obstetrician, etc.). Unluckily, many such given ad-
vices are not evidence-based, but simply emphasize not
circumstantial assessments of the lactation risk.
We believe that mothers treated with AEDs should be
encouraged to start breastfeeding immediately after child-
birth, even if a definite and complete evidence-based in-
formation has yet not been collected. In fact, breast milk
should not be considered as a “presumed guilty”, because,
after a complete scrutiny, only very few AEDs resulted
contraindicated during breastfeeding [24,72,73].
The present study is not without limitations. First of
all, we did not conduct a systematic review of the pub-
lished literature, but we offered a synopsis of the two
most updated and authoritative clinical sources on the
lactation risk (namely: Hale and Toxnet). Secondly, the
existing reports on the lactation risks of medications in
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anecdotal or based on case series and therefore of poor
methodological quality. However, we should remember
that any recorded side-effect, while biologically and
pharmacologically plausible in the nursing infant, is
rarely attributable with certainty to a particular drug
taken by her/his mother [74].
Conclusions
According to the present review, we grouped AEDs into
3 main classes of lactation risk:
1. AEDs safe to use during lactation. Carbamazepine,
valproic acid and phenytoin are compatible with
breastfeeding. Phenobarbital and primidone are also
compatible, although particular attention should be
paid on infant monitoring, possibly measuring the
infant plasma drug level.
2. AEDs with a less documented safety profile during
lactation (moderately safe). Gabapentin, lamotrigine,
levetiracetam, oxcarbazepine, pregabalin and vigabatrin
may be used during lactation, but their lowest dose
should be prescribed. The nursing infant should be
carefully monitored and, if required, the infant drug
plasma-level tested. When lamotrigine is taken by the
mother, it is advisable to check the presence of
thrombocytopenia in the nursing infant. Although
based on scarce available data, tiagabine and topiramate
can be considered compatible with breastfeeding.
3. AEDs contraindicated during lactation.
Ethosuximide should be used only when there are
no alternatives and after informed consent of the
mother. Lastly, zonisamide and the continuous use
of diazepam or clonazepam should be avoided.
Even if an AED can be safely taken by the breastfeeding
mother, it is a good clinical practice to call the mother
attention on the behavior, sleep, feeding patterns and
growth of the nursing infant, especially in the first
2 months of life [75]. When possible, we might advice to
monitor the infant plasma levels, especially for the moder-
ately safe AEDs. However, we are aware that there is no
clear agreement on when to test them. We believe that
after 4–8 weeks is a reasonable time window, as, if the
child is fully breastfed, breast milk would have reached its
highest production and the consequent intake by the
nursing infant would be at the maximum.
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